|
|
|
DOXORUBICIN DRUG PATHWAY (PW:0001455)
Description
Doxorubucin (DOX, trade name Adriamycin) is an anthracycline derived from Streptomyces bacterium Streptomyces peucetius var. caesius. DOX is used in the treatment of several solid cancers, leukemia and lymphomas. The drug is composed of a planar aromatic ring with an anthraquinone chromophore and a sugar group. Once taken up by the cell and inside the nucleus for which it has a high affinity, the planar ring structure intercalates between adjacent DNA base pairs, preferentially GC base pairs. DOX can form DNA adducts, binds to DNA and topoisomerases and inhibits DNA replication and transcription. It promotes DNA double-strand breaks (DSBs) and the DNA damage prompts various responses, including cell cycle arrest and apoptosis, primarily via activation of p53 pathway but also independent of it, with beneficial, if tumor cells, or otherwise detrimental consequences. While toxic to the tumor cell, DOX is also toxic to all other cell types. The cardiotoxicity of the drug is the main and the most severe adverse effect, and the cardiomyopathies associated with DOX can eventually lead to heart failure. The formation of reactive oxygen species (ROS), impaired iron homeostasis and mitochondrial dysfunction are thought to underlie the cardiotoxicity of DOX. Although more than 50% of DOX is eliminated unchanged, the drug undergoes several types of transformation such as two- and one-electron reduction and to a smaller extent deglycosidation. Free radical generation is a feature of DOX metabolism. The drug can interact with iron and generate hydroxyl radical and with the iron-responsive elements (IRE) regions of mRNAs, it can impact on the function of iron regulatory proteins (IRPs) and disturb iron homeostasis. In addition, DOX localizes to mitochondria, forms adducts with mitochondrial DNA, interacts with cardiolipin - an essential component of inner mitochondrial membrane, and is capable of impacting on a number of proteins/enzymes important for mitochondrial function. Doxorubicin is also administered as a pegylated liposomal product. ...(less)
|
Pathway Diagram:
|
|
Genes in Pathway:
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
|
ISO
|
|
RGD |
PMID:25895646 |
RGD:10395260 |
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:83,945,735...83,976,874
|
|
G
|
Top2b
|
DNA topoisomerase II beta
|
|
ISO
|
|
RGD |
PMID:25895646 |
RGD:10395260 |
NCBI chr15:9,051,340...9,111,721
Ensembl chr15:9,051,341...9,112,085
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
|
ISO
|
|
SMPDB RGD |
PMID:21048526 |
SMP:00650, RGD:10395261 |
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
|
ISO
|
|
SMPDB |
|
SMP:00650 |
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
|
ISO
|
|
SMPDB RGD |
PMID:21048526 |
SMP:00650, RGD:10395261 |
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
|
ISO
|
|
RGD |
PMID:21048526 |
RGD:10395261 |
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
|
ISO
|
|
SMPDB RGD |
PMID:21048526 |
SMP:00650, RGD:10395261 |
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G
|
Akr1a1
|
aldo-keto reductase family 1 member A1
|
|
ISO
|
|
SMPDB RGD |
PMID:21048526 PMID:19442138 |
SMP:00650, RGD:10395261, RGD:10395262 |
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G
|
Akr1c3
|
aldo-keto reductase family 1, member C3
|
|
ISO
|
|
SMPDB RGD |
PMID:21048526 |
SMP:00650, RGD:10395261 |
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G
|
Cbr1
|
carbonyl reductase 1
|
|
ISO
|
|
SMPDB RGD |
PMID:21048526 PMID:19442138 |
SMP:00650, RGD:10395261, RGD:10395262 |
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G
|
Cbr3
|
carbonyl reductase 3
|
|
ISO
|
|
SMPDB RGD |
PMID:21048526 PMID:19442138 |
SMP:00650, RGD:10395261, RGD:10395262 |
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G
|
Ndufs2
|
NADH:ubiquinone oxidoreductase core subunit S2
|
|
ISO
|
|
SMPDB |
|
SMP:00650 |
NCBI chr13:83,654,402...83,671,474
Ensembl chr13:83,654,406...83,671,420
|
|
G
|
Ndufs3
|
NADH:ubiquinone oxidoreductase core subunit S3
|
|
ISO
|
|
SMPDB |
|
SMP:00650 |
NCBI chr 3:76,876,646...76,883,824
Ensembl chr 3:76,876,646...76,883,824
|
|
G
|
Ndufs7
|
NADH:ubiquinone oxidoreductase core subunit S7
|
|
ISO
|
|
SMPDB |
|
SMP:00650 |
NCBI chr 7:9,452,556...9,460,135
Ensembl chr 7:9,450,392...9,460,195
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
|
ISO
|
|
SMPDB RGD |
PMID:19442138 |
SMP:00650, RGD:10395262 |
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
|
ISO
|
|
SMPDB RGD |
PMID:19442138 |
SMP:00650, RGD:10395262 |
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G
|
Por
|
cytochrome p450 oxidoreductase
|
|
ISO
|
|
SMPDB |
|
SMP:00650 |
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G
|
Ralbp1
|
ralA binding protein 1
|
|
ISO
|
|
SMPDB RGD |
PMID:21048526 |
SMP:00650, RGD:10395261 |
NCBI chr 9:105,456,425...105,493,235
Ensembl chr 9:105,456,425...105,492,707
|
|
G
|
Slc22a16
|
solute carrier family 22 member 16
|
|
ISO
|
|
SMPDB RGD |
PMID:21048526 |
SMP:00650, RGD:10395261 |
NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019
|
|
G
|
Xdh
|
xanthine dehydrogenase
|
|
ISO
|
|
SMPDB RGD |
PMID:19442138 |
SMP:00650, RGD:10395262 |
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
|
Pathway Gene Annotations |
References Associated with the doxorubicin drug pathway:
- Rochette L, etal., Trends Pharmacol Sci. 2015 Jun;36(6):326-48. doi: 10.1016/j.tips.2015.03.005. Epub 2015 Apr 17.
- Thorn CF, etal., Pharmacogenet Genomics. 2011 Jul;21(7):440-6. doi: 10.1097/FPC.0b013e32833ffb56.
- Mordente A, etal., Curr Med Chem. 2009;16(13):1656-72.
- Pommier Y ACS Chem Biol. 2013 Jan 18;8(1):82-95. doi: 10.1021/cb300648v. Epub 2013 Jan 4.
- Tacar O, etal., J Pharm Pharmacol. 2013 Feb;65(2):157-70. doi: 10.1111/j.2042-7158.2012.01567.x. Epub 2012 Aug 2.
- Gammella E, etal., Front Pharmacol. 2014 Feb 26;5:25. doi: 10.3389/fphar.2014.00025. eCollection 2014.
- Xu X, etal., Mol Pharmacol. 2005 Aug;68(2):261-71. Epub 2005 May 9.
- Yang F, etal., Biochim Biophys Acta. 2014 Jan;1845(1):84-9. doi: 10.1016/j.bbcan.2013.12.002. Epub 2013 Dec 19.
- Octavia Y, etal., J Mol Cell Cardiol. 2012 Jun;52(6):1213-25. doi: 10.1016/j.yjmcc.2012.03.006. Epub 2012 Mar 21.
- Dirks-Naylor AJ Life Sci. 2013 Dec 5;93(24):913-6.
- Kagan VE, etal., Chem Phys Lipids. 2014 Apr;179:64-9. doi: 10.1016/j.chemphyslip.2013.11.010. Epub 2013 Dec 1.
- Paradies G, etal., Biochim Biophys Acta. 2014 Apr;1837(4):408-17. doi: 10.1016/j.bbabio.2013.10.006. Epub 2013 Oct 29.
- Li XX, etal., J Histochem Cytochem. 2015 May;63(5):301-11. doi: 10.1369/0022155415574818. Epub 2015 Feb 11.
- Claypool SM and Koehler CM, Trends Biochem Sci. 2012 Jan;37(1):32-41. doi: 10.1016/j.tibs.2011.09.003. Epub 2011 Oct 17.
- Edwards AV, etal., Circ Cardiovasc Genet. 2011 Oct;4(5):575. doi: 10.1161/CIRCGENETICS.110.957787.
- Gabizon A, etal., Eur J Pharm Sci. 2012 Mar 12;45(4):388-98. doi: 10.1016/j.ejps.2011.09.006. Epub 2011 Sep 10.
|
|
Ontology Path Diagram:
|
Import into Pathway Studio:
|
|